Cited by 8Liver Disease Diagnosis and TreatmentGenetic and Clinical Aspects of Sex Determination and Chromosomal AbnormalitiesLiver Disease and Transplantation

Focus on liver function abnormalities in patients with Turner syndrome: risk factors and evaluation of fibrosis risk

Bourcigaux, Nathalie, Dubost, Emma, Buzzi, Jean-Claude, Donadille, Bruno, Corpechot, Christophe, Poujol-Robert, Armelle, Christin-Maitre, Sophie·2023·The Journal of Clinical Endocrinology & Metabolism

Abstract

CONTEXT: Liver function abnormalities (LFAs) have been described in patients with Turner syndrome (TS). Although a high risk of cirrhosis has been reported, there is a need to assess the severity of liver damage in a large cohort of adult patients with TS. OBJECTIVE: Evaluate the types of LFAs and their respective prevalence, search for their risk factors, and evaluate the severity of liver impairment by using a noninvasive fibrosis marker. METHODS: This was a monocentric retrospective cross-sectional study. Data were collected during a day hospital visit. The main outcome measures were liver enzymes (alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase), FIB-4 score, liver ultrasound imaging, elastography, and liver biopsies, when available. RESULTS: 264 patients with TS were evaluated at a mean age of 31.15 ± 11.48 years. The overall prevalence of LFAs was 42.8%. The risk factors were age, body mass index, insulin resistance, and an X isochromosome (Xq). The mean FIB-4 sore of the entire cohort was 0.67 ± 0.41. Less than 10% of patients were at risk of developing fibrosis. Cirrhosis was observed in 2/19 liver biopsies. There was no significant difference in the prevalence of LFAs between premenopausal patients with natural cycles and those receiving hormone replacement therapy (P = .063). A multivariate analysis adjusted for age showed no statistically significant correlation between hormone replacement therapy and abnormal gamma-glutamyl transferase levels (P = .12). CONCLUSION: Patients with TS have a high prevalence of LFA. However, 10% are at high risk of developing fibrosis. The FIB-4 score is useful and should be part of the routine screening strategy. Longitudinal studies and better interactions with hepatologists should improve our knowledge of liver disease in patients with TS.

Integrity signals

Registry

Crossref · 10.1210/clinem/dgad108

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • LFA, defined as increased liver enzymes, are present in 40%-80% of patients with TS, with more recent studies on the high end of that estimate.

    “LFA, defined as increased liver enzymes are present in 40%-80% of patients with TS, with more recent studies on the high end of that estimate.342-344,714,715”
  • Recent studies suggest that FIB-4 scores are lower than expected in patients with TS, possibly reflecting that liver diseases are mild in most cases.

    “Recent studies suggest that FIB-4 scores are lower than expected in patients with TS,714,715 possibly reflecting that liver diseases are mild in most cases.”
  • Even young children with TS without risk factors have a higher prevalence of LFA.

    “Risk factors for LFA are age, obesity, insulin resistance, and Xq isochromosome, however even young children with TS without risk factors have a higher prevalence of LFA.342-344,714,715”
  • Risk factors for LFA in TS are age, obesity, insulin resistance, and Xq isochromosome.

    “Risk factors for LFA are age, obesity, insulin resistance, and Xq isochromosome, however even young children with TS without risk factors have a higher prevalence of LFA.342-344,714,715”
  • A recent study has shown that there is no difference in the prevalence of LFA between women with TS who have endogenous ovarian function compared to those receiving HRT.

    “A recent study has shown that there is no difference in the prevalence of LFA between women with TS who have endogenous ovarian function compared to those receiving HRT.715”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Bourcigaux, N., Dubost, E., Buzzi, J.-C., Donadille, B., Corpechot, C., Poujol-Robert, A., & Christin-Maitre, S.
Affiliations
  • Sorbonne Université (FR)
  • Assistance Publique – Hôpitaux de Paris (FR)
  • Inserm (FR)
  • Department of Hepatology, Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis (MIVB-H), French Network for Rare Liver Diseases in Children and Adults FILFOIE, European Reference Network (ERN) RARE-LIVER, Saint-Antoine Hospital & Research Center, Assistance Publique—Hôpitaux de Paris (APHP), Inserm & Sorbonne University , 75011 Paris , France
  • Endocrine and Reproductive Medicine Unit, Center of Rare Endocrine Diseases of Growth and Development (CMERCD), FIRENDO, Endo ERN Hôpital Saint-Antoine, Sorbonne University , Assistance Publique–Hôpitaux de Paris, 75012 Paris , France
Corresponding author
Bourcigaux, Nathalie
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2023-03-10
Volume
108
Issue
9
Pages
2255-2261
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W4323808234
Cited by
8
References
33
Citations by year
2026: 1 · 2025: 5 · 2024: 2
FWCI
1.60
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Keywords
Turner syndrome, liver dysfunction, liver fibrosis, liver cirrhosis, FIB-4, non-invasive fibrosis markers, liver enzymes, gamma-glutamyl transferase, insulin resistance, hormone replacement therapy, liver ultrasound elastography, liver biopsy, risk factors
MeSH terms
Adult, Cross-Sectional Studies, gamma-Glutamyltransferase, Humans, Liver, Liver Cirrhosis, Liver Diseases, Retrospective Studies, Risk Factors, Turner Syndrome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review